New sedative may improve care for critically ill patients
NCT ID NCT07155265
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two sedatives—remimazolam and midazolam—in 180 critically ill adults who need a breathing tube and medications for shock. The goal is to see if remimazolam keeps patients at the right sedation level more consistently without needing extra drugs. Researchers will also check how it affects recovery time, delirium, and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Remimazolam besylate (a short-acting sedative)
- What this could lead to
- If it works, this could offer a safer, more controllable sedation option for ICU patients on breathing machines and shock medications.
- What could go wrong
- This is a single-center phase 3 trial with 180 participants, so results may not apply broadly. Both drugs are sedatives with risks like low blood pressure or delayed awakening.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS; MECHANICAL VENTILATION; SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••